The Global Acute Ischemic Stroke (AIS) Market primarily deals with providing diagnostic and therapeutic solutions for patients suffering from acute ischemic stroke. AIS occurs due to blockage of blood vessels supplying blood to the brain, which can be caused by thrombosis or embolism that restricts blood flow. The market offers diversified products such as diagnostic imaging devices, thrombolytic drugs, antihypertensive drugs, anticoagulants and others. The early diagnosis through CT or MRI scans followed by appropriate thrombolytic or antithrombotic therapies within the therapeutic window plays a vital role in reducing mortality and neurological deficits associated with the condition.
The Global AIS Market is estimated to be valued at US$ 10612.22 Bn in 2024 and is expected to exhibit a CAGR of 18% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the Acute Ischemic Stroke market are F. Hoffmann-La Roche AG, Boehringer Ingelheim, Bayer AG, Pfizer Inc., Biogen, Daiichi Sankyo, Bristol-Myers Squibb, Johnson & Johnson, AstraZeneca, SanBio and Athersys Inc. These players are focusing on developing new products and expanding geographically.
The growing geriatric population susceptible to AIS and rising awareness about early diagnosis and treatment is increasing the demand for various diagnostic and therapeutic products in the market. As per estimates, over 17 million people suffer an acute stroke annually worldwide.
The market players are expanding their presence globally, especially in emerging nations to tap the increasing healthcare needs. Strategic collaborations with hospitals, diagnostic centers, distribution partners are helping them strengthen global footprint.
Market drivers
The Acute Ischemic Stroke Market Growth can be highly attributed to rising geriatric population globally. As age is the primary risk factor for AIS, increased life expectancy has augmented the number of elderly population liable to develop the condition. As per WHO, there were approximately 703 million people aged 65 years or over in 2019 and their numbers are projected to cross 1.5 billion by 2050. This widening geriatric demographic presents huge patient pool opportunity for AIS market.
The current geopolitical tensions and economic uncertainties across several regions are anticipated to impact the growth of the AIS market during the forecast period. The ongoing Russia-Ukraine war and sanctions imposed by Western nations have disrupted the global supply chains and economies of many Eastern European countries. This has constrained the healthcare spending and prioritization of non-communicable diseases in these regions. At the same time, the increasing prevalence of lifestyle diseases and growing geriatric population continue to drive the demand for effective AIS treatments. The market players need to closely monitor the geopolitical changes and Devise contingency plans to minimize supply disruptions. They also need to consider expanding their manufacturing footprints across multiple regions and countries to reduce overdependence on single markets. Partnering with local players can help gain better access to emerging patient pools in developing Asian and Latin American countries.
The North American region currently holds the largest share in the global AIS market in terms of value, owing to the well-established healthcare systems, high patient awareness levels, and sizable research and development investments by leading pharmaceutical companies in the region. However, the growing healthcare expenditure and rapidly expanding patient population make the Asian markets an attractive avenue for future growth. Countries like China and India are expected to contribute significantly to the AIS market growth during the forecast period due to rising incidences of stroke, increasing penetration of advanced treatment options, and availability of low-cost generics.
The Asia Pacific region, especially China and India, are poised to witness the fastest growth in the global AIS market during the forecast period. This is majorly attributed to the growing geriatric population, increasing healthcare expenditure, expanding network of hospitals and diagnostic centers, and rising awareness about early stroke diagnosis and management in these emerging Asian economies. Furthermore, the availability of low-cost generic drugs and favorable government policies supporting the local manufacturing of biosimilars is attracting global pharmaceutical players to invest in the Asia Pacific AIS market.
Central and Eastern European countries like Poland, Czech Republic, and Hungary also exhibit high growth potential for AIS treatments. The increasing uptake of advanced recombinant t-PA therapies for thrombolysis and rising acceptance of endovascular interventions are fueling the CEE AIS market growth. Rising healthcare investments in these nations according to European standards and presence of prominent medical device players are contributing further to market development. However, post-pandemic economic challenges and ongoing geopolitical conflicts might temporarily threaten market expansion across some CEE countries to an extent. Therefore, pharma companies need to adopt patient-centric pricing strategies and effectively communicate the long-term benefits of early stroke intervention in the CEE region.
Get more insights on Acute Ischemic Stroke Market
